The substantial morbidity and morta...

The substantial morbidity and mortality caused by dint of influenza has stimulated the progressive growth of antiviral agents such as zanamivir and oseltamivir to treat and stop acute influenza infections without the adverse results of earlier drugs. Cooper and colleagues analyzed the evidence to determine the efficacy and safety of these brace agents.

They searched electronic and other databases, respects and manufacturers' data to identify all published and unpublished randomized double-blind clinical trials of the treatment or prevention of naturally occurring influenza with zanamivir or oseltamivir. They considered three disposes of patients: children (12 years and younger), healthy human frames 12 to 65 years of age, and high-risk living bodys (65 years and older or having chronic medical conditions). The principal issue measures were time to relief of symptoms and complications requiring antibiotic therapy. Hospital admissions and time to resumption of normal activities also were considered. For preventive studies, the principal last point was the number of bodily forms with laboratory-confirmed symptomatic influenza.

Of 62 treatment studies identified, merely eight studies of zanamivir and nine studies of oseltamivir met eligibility and quality criteria. For zanamivir, the reduction in median time to alleviation of symptoms compared with placebo ranged from 08 days in healthy adults to individual day in children. The efficiency was greater (one day in children and couple days in high-risk patients) in someones with confirmed influenza. The remainings of complications requiring antibiotics also were reduc in brace studies. Patients treated with oseltamivir showed a reduction in median time to alleviation of symptoms (04 days in high-risk adults and 09 days in children) with an increased import in laboratory-confirmed influenza (0.4 days in high-risk adults and 15 days in children). Complications requiring antibiotics were reported to be les habitual in one study of children and common study of adults, but this difference merely reached statistical significance in the influenza-positive patients.

Of the 18 trials of prevention of influenza, no other than three trials of zanamivir and four trials of oseltamivir met the criteria for inclusion in the analysis. Zanamivir showed an 81 percent relative reduction in the remainings of household contacts developing laboratory-confirmed influenza, and oseltamivir was associated with a 90 percent reduction. Oseltamivir also was associated with a 92 percent reduction in the singles of laboratory-confirmed symptomatic influenza when used for seasonal prophylaxis in a residential somewhat advanced in life care facility and a 74 percent reduction in a healthy population.

The authors close that treatment of otherwise healthy adults or children with zanamivir or oseltamivir within 48 hours of symptom charge reduces the duration of symptoms of influenza from 0.4 days to one day and diminishes the chances of receiving antibiotics for complications by the agency of up to 43 percent. The ability of these agents to obviate influenza in exposed persons is reported to range from 70 to 90 percent depending forward the population and strategy used. Further research is necessary, particularly into the character of these drugs in preventing influenza outbreaks in children and institutionalized somewhat old patients.

Cooper NJ et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controll trials. BMJ June 7 2003;326:1235-40

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group